Atum licenses cell line development tools to Rentschler Biopharma

By The Science Advisory Board staff writers

October 14, 2020 -- Rentschler Biopharma has signed a full contract development and manufacturing organization (CDMO) license agreement for Atum's Leap-In transposase platform.

Under the agreement, Atum will provide Rentschler full access to its Leap-In Transposase platform. Atum's technology will advance Renstchler's cell line development services and capabilities and complement existing services offered through its CDMO strategic partner network. These services include the Chinese hamster ovary-glutamine synthetase-knockout (CHO-GS-KO) platform for difficult-to-express proteins, that together with the leap-in transposase platform will be well-suited for high-quality protein expression for designer protein therapeutics.

The Leap-In Transposase technology platform combines proprietary recoding algorithms, unique vector elements, and transposon-based mechanism for efficient insertion of genetically stable elements into the genome. The platform can be used to develop standard antibodies and multichain therapeutics proteins, such as bispecific monoclonal antibodies.

The companies will offer an additional service that will rapidly and robustly produce stable, high titer manufacturing cell lines to support organizations in moving biopharmaceuticals to market faster and with lower manufacturing risk.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.